Results from this MBC cohort provided insight on the relationship between tumor-based CCT2 expression and shed epithelial CTCs in breast cancer, suggesting that CCT2 may perform better as a marker for CTCs than standard epithelial markers alone, which is further explored. This evidence concerns the gene CCT2 and neoplasm.